Skip to content
2000
Volume 31, Issue 14
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Aims

This study aims to identify and evaluate promising therapeutic proteins and compounds for breast cancer treatment through a comprehensive database search and molecular docking analysis.

Background

Breast cancer (BC), primarily originating from the terminal ductal-lobular unit of the breast, is the most prevalent form of cancer globally. In 2020, an estimated 2.3 million new cases were reported, resulting in approximately 685,000 deaths. Mutations in the BRCA1 and BRCA2 genes are well-established in hereditary breast cancer. The identification of effective therapeutic proteins for BC remains a complex and evolving area of research.

Objective

This study aims to identify and evaluate promising therapeutic proteins and compounds specific to breast cancer through a comprehensive database search and molecular docking analysis.

Methods

A rigorous search was conducted within the National Cancer Institute (NCI), NCI Metathesaurus, SIGnaling Network Open Resource (SIGNOR), Human Protein Atlas (HPA), and the Human Phenotype Ontology (HPO) to shortlist proteins linked to BC (CUI C0678222). Recent studies were reviewed to understand the administration of CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with endocrine therapy for HR-positive and HER2-negative breast cancer. Anticancer compound libraries available at ZINC and PubChem were analyzed. Compounds were evaluated based on their binding energies with CDK4 protein, a rationally selected druggable target.

Results

Key proteins linked to breast cancer were identified through database searches. Proliferation, apoptosis, and G1/S transition pathways were frequently found dysregulated in breast cancer. ZINC13152284 exhibited the strongest binding energy at -10.9 Kcal/mol, followed by ZINC05492794 with a binding energy of-10.4 Kcal/mol. Preexisting drugs showed lower binding energies with the CDK4 protein.

Conclusion

The study highlights the importance of drug repurposing as a strategy for the safe and effective treatment of breast cancer. Synthetic inhibitors often cause severe side effects, emphasizing the need for novel targets and compounds with better therapeutic profiles. Molecular docking identified promising compounds from the ZINC database, suggesting potential new avenues for breast cancer therapy.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128346655241112104045
2025-01-13
2025-07-03
Loading full text...

Full text loading...

References

  1. EhemanC.R. ShawK.M. RyersonA.B. MillerJ.W. AjaniU.A. WhiteM.C. The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004.Cancer Epidemiol. Biomarkers Prev.20091861763176910.1158/1055‑9965.EPI‑08‑1082 19454615
    [Google Scholar]
  2. MakkiJ. Diversity of breast carcinoma: Histological subtypes and clinical relevance.Clin. Med. Insights Pathol.20158233110.4137/CPath.S31563
    [Google Scholar]
  3. AladienY. Assessment Of Women’s Knowledge And Awareness About Breast Cancer Early Detection and Screening. In: Women Aged below 40 Years in Palestine.Faculty of Graduate Studies Assessment of Women’s Knowledge And Awareness2024
    [Google Scholar]
  4. RockC.L. ThomsonC.A. SullivanK.R. American Cancer Society nutrition and physical activity guideline for cancer survivors.CA Cancer J. Clin.202272323026210.3322/caac.21719 35294043
    [Google Scholar]
  5. LiuN. YangD.W. WuY.X. Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: An up-to-date overview and comparison with those in Japan and South Korea.BMC Cancer202222182610.1186/s12885‑022‑09923‑4 35906569
    [Google Scholar]
  6. FengY. SpeziaM. HuangS. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.Genes Dis.2018527710610.1016/j.gendis.2018.05.001 30258937
    [Google Scholar]
  7. KamińskaM. CiszewskiT. Łopacka-SzatanK. MiotłaP. StarosławskaE. Breast cancer risk factors.Prz. Menopauz.201514319620210.5114/pm.2015.54346
    [Google Scholar]
  8. OzsoyA. BarçaN. Akdal DolekB. The relationship between breast cancer and risk factors: A single-center study.Eur. J. Breast Health201713314514910.5152/tjbh.2017.3180 28894854
    [Google Scholar]
  9. SunY.S. ZhaoZ. YangZ.N. Risk factors and preventions of breast cancer.Int. J. Biol. Sci.201713111387139710.7150/ijbs.21635 29209143
    [Google Scholar]
  10. HartmannL.C. SellersT.A. FrostM.H. Benign breast disease and the risk of breast cancer.N. Engl. J. Med.2005353322923710.1056/NEJMoa044383 16034008
    [Google Scholar]
  11. DupontW.D. ParlF.F. HartmannW.H. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia.Cancer19937141258126510.1002/1097‑0142(19930215)71:4<1258::AID‑CNCR2820710415>3.0.CO;2‑I 8435803
    [Google Scholar]
  12. BarnardM.E. BoekeC.E. TamimiR.M. Established breast cancer risk factors and risk of intrinsic tumor subtypes.Biochim. Biophys. Acta2015185617385 26071880
    [Google Scholar]
  13. ColditzG.A. KaphingstK.A. HankinsonS.E. RosnerB. Family history and risk of breast cancer: Nurses’ health study.Breast Cancer Res. Treat.201213331097110410.1007/s10549‑012‑1985‑9 22350789
    [Google Scholar]
  14. CicatielloL. AddeoR. SassoA. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter.Mol. Cell. Biol.200424167260727410.1128/MCB.24.16.7260‑7274.2004 15282324
    [Google Scholar]
  15. VermeulenK. BernemanZ.N. Van BockstaeleD.R. Cell cycle and apoptosis.Cell Prolif.200336316517510.1046/j.1365‑2184.2003.00267.x 12814432
    [Google Scholar]
  16. SaidT.K. ConneelyO.M. MedinaD. O’MalleyB.W. LydonJ.P. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo.Endocrinology199713893933393910.1210/endo.138.9.5436 9275084
    [Google Scholar]
  17. AdonT. ShanmugarajanD. KumarH.Y. CDK4/6 inhibitors: A brief overview and prospective research directions.RSC Advances20211147292272924610.1039/D1RA03820F 35479560
    [Google Scholar]
  18. ChagaletiB.K. SaravananV. VellapandianC. KathiravanM.K. Exploring cyclin-dependent kinase inhibitors: A comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach.RSC Advances20231348337703378510.1039/D3RA05672D 38019988
    [Google Scholar]
  19. TangW. ShenT. ChenZ. In silico discovery of potential PPI inhibitors for anti-lung cancer activity by targeting the CCND1-CDK4 complex via the P21 inhibition mechanism.Front Chem.202412140457310.3389/fchem.2024.1404573 38957406
    [Google Scholar]
  20. FinnR.S. AleshinA. SlamonD.J. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.Breast Cancer Res.20161811710.1186/s13058‑015‑0661‑5 26857361
    [Google Scholar]
  21. O’LearyB. FinnR.S. TurnerN.C. Treating cancer with selective CDK4/6 inhibitors.Nat. Rev. Clin. Oncol.201613741743010.1038/nrclinonc.2016.26 27030077
    [Google Scholar]
  22. KoesD.R. CamachoC.J. ZINCPharmer: Pharmacophore search of the ZINC database.Nucleic Acids Res.201240W1W409-1410.1093/nar/gks378 22553363
    [Google Scholar]
  23. Lo SurdoP. IannuccelliM. ContinoS. SIGNOR 3.0, the SIGnaling network open resource 3.0: 2022 update.Nucleic Acids Res.202351D1D631D63710.1093/nar/gkac883 36243968
    [Google Scholar]
  24. LüleciH.B. YılmazA. Robust and rigorous identification of tissue-specific genes by statistically extending tau score.BioData Min.20221513110.1186/s13040‑022‑00315‑9 36494766
    [Google Scholar]
  25. TrottO. OlsonA.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.J. Comput. Chem.201031245546110.1002/jcc.21334 19499576
    [Google Scholar]
  26. AshrafS.A. ElkhalifaA.E.O. MehmoodK. Multi-targeted molecular docking, pharmacokinetics, and drug-likeness evaluation of okra-derived ligand abscisic acid targeting signaling proteins involved in the development of diabetes.Molecules20212619595710.3390/molecules26195957 34641501
    [Google Scholar]
  27. ElkhalifaA.E.O. Al-ShammariE. KuddusM. Structure-based multi-targeted molecular docking and dynamic simulation of soybean-derived Isoflavone genistin as a potential breast cancer signaling proteins inhibitor.Life (Basel)2023138173910.3390/life13081739 37629596
    [Google Scholar]
  28. LaamariY. BimoussaA. MouradF. Multitargeted molecular docking and dynamics simulation of thymol-based chalcones against cancer protein markers: Synthesis, characterization, and computational study.J. Mol. Struct.2024131713911610.1016/j.molstruc.2024.139116
    [Google Scholar]
  29. CaseD.A. CheathamT.E.III DardenT. The Amber biomolecular simulation programs.J. Comput. Chem.200526161668168810.1002/jcc.20290 16200636
    [Google Scholar]
  30. WangJ. WangW. KollmanP.A. CaseD.A. Automatic atom type and bond type perception in molecular mechanical calculations.J. Mol. Graph. Model.200625224726010.1016/j.jmgm.2005.12.005 16458552
    [Google Scholar]
  31. MarkP. NilssonL. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K.J. Phys. Chem. A2001105439954996010.1021/jp003020w
    [Google Scholar]
  32. AlshammariS.O. AlshammariQ.A. Natural product-derived ALK inhibitors for treating ALK-driven lung cancers: An in silico study.Mol. Divers.202411410.1007/s11030‑024‑10953‑2 39115579
    [Google Scholar]
  33. FaragoO. Langevin thermostat for robust configurational and kinetic sampling.Physica A201953412221010.1016/j.physa.2019.122210
    [Google Scholar]
  34. ElberR. RuymgaartA.P. HessB. SHAKE parallelization.Eur. Phys. J. Spec. Top.2011200121122310.1140/epjst/e2011‑01525‑9 22368766
    [Google Scholar]
  35. NagarajB.S. NambooriP.K.K. AkeyK.S. Vitamin D analog calcitriol for breast cancer therapy; An integrated drug discovery approach.J. Biomol. Struct. Dyn.20234120110171104310.1080/07391102.2023.2199866 37054526
    [Google Scholar]
  36. PackiapalavesamS.D. SaravananV. MahajanA.A. Identification of novel CA IX inhibitor: Pharmacophore modeling, docking, DFT, and dynamic simulation.Comput. Biol. Chem.202411010807310.1016/j.compbiolchem.2024.108073 38678727
    [Google Scholar]
  37. BraalC.L. JongbloedE.M. WiltingS.M. MathijssenR.H.J. KoolenS.L.W. JagerA. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: Similarities and differences.Drugs202181331733110.1007/s40265‑020‑01461‑2 33369721
    [Google Scholar]
  38. DingL. CaoJ. LinW. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer.Int. J. Mol. Sci.2020216196010.3390/ijms21061960 32183020
    [Google Scholar]
  39. ChenD. OezguenN. UrvilP. FergusonC. DannS.M. SavidgeT.C. Regulation of protein-ligand binding affinity by hydrogen bond pairing.Sci. Adv.201623e150124010.1126/sciadv.1501240 27051863
    [Google Scholar]
  40. YuntaM.J. It is important to compute intramolecular hydrogen bonding in drug design.Am J Model Optim2017512457
    [Google Scholar]
  41. BowersK. ChowE. XuH. Scalable algorithms for molecular dynamics simulations on commodity clusters.Proceedings of the ACM/IEEE SC2006 Conference on High Performance Networking and Computing.Tampa, FL, USA, November 11-172006
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128346655241112104045
Loading
/content/journals/cpd/10.2174/0113816128346655241112104045
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test